Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents
ChemMedChem · 2025
DOI: 10.1002/cmdc.202400533 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Keamogetswe Sechoaro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, 11 Hoffmann Street, Potchefstroom, 2…. Hauptthemen laut MEDLINE: Parasitic Sensitivity Tests, Antiprotozoal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation (NRF), North-West University, Potchefstroom Campus, Japan Society for the Promotion of Science (JSPS), KAKENHI.
Abstract (Originalsprache)
Neglected tropical diseases are a group of infectious diseases with a high endemicity in developing countries of Africa, Asia, and the Americas. Treatment for these diseases depends solely on chemotherapy, which is associated with severe side effects, toxicity, and the development of parasitic resistance. This highlights a critical need to develop new and effective drugs to curb these diseases. As a result, a series of novel isatinylhydantoin derivatives were synthesized and evaluated for in vitro anti ‐ kinetoplastid activity against seven human‐ or animal‐infective Trypanosoma and two human‐infective Leishmania species. The synthesized derivatives were tested for potential cytotoxicity against human, animal, and parasite host‐related cell lines. The isatinylhydantoin hybrid 4 b bearing 5‐chloroisatin and p ‐bromobenzyl moieties, showed strong trypanocidal activity against blood‐stage T. congolense parasites; however, the promising in vitro trypanocidal potency of 4 b could not be translated to in vivo treatment efficacy in a preliminary animal study. Compounds 5 , 2 b , and 5 b , were the most active against amastigotes of L. donovani , showing higher leishmanicidal activity than the reference drug, amphotericin B. These compounds were identified as early antileishmanicidal leads, and future investigations will focus on confirming their antileishmanial potential through in vivo efficacy evaluation as well as their exact mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, 11 Hoffmann Street, Potchefstroom, 2520, South Africa.
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido, 080-8555, Japan.
ORCID-Profile: Keamogetswe Sechoaro, Janine Aucamp, Christina Kannigadu, Helena D Janse van Rensburg, Keisuke Suganuma, David D N'Da
Förderung
- National Research Foundation (NRF)
- North-West University, Potchefstroom Campus
- Japan Society for the Promotion of Science (JSPS), KAKENHI
- [Grants-in-Aid for Young Scientists (B)
- Ohyama Health Foundation, Inc.
Zitieren
APA
Sechoaro, K., Aucamp, J., Kannigadu, C., Janse van Rensburg, H. D., Suganuma, K., & N'Da, D. D. (2025). Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents. ChemMedChem. https://doi.org/10.1002/cmdc.202400533
Vancouver
Sechoaro K, Aucamp J, Kannigadu C, Janse van Rensburg HD, Suganuma K, N'Da DD. Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents. ChemMedChem. 2025. doi:10.1002/cmdc.202400533
BibTeX
@article{Sechoaro2025,
author = {Sechoaro, Keamogetswe and Aucamp, Janine and Kannigadu, Christina and Janse van Rensburg, Helena D and Suganuma, Keisuke and N'Da, David D},
title = {Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202400533}
}
EUVIMED